Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TYSABRI
- Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
- A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- AttackMS - Treatment of People With Inflammatory Demyelination Suggestive of MS, or Definite MS, at First Presentation
- Natalizumab and Chronic Inflammation
- Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
- Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
- Inflammatory Response In Schizophrenia
- Clinical Disease Activity With Long Term Natalizumab Treatment
- Natalizumab in Inclusion Body Myositis (IBM)
- Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab
- Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
- Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
- Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
- Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
- Natalizumab Subcutaneous Immunogenicity and Safety Study
- Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
- Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
- Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
- Biogen Multiple Sclerosis Pregnancy Exposure Registry
- Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
- NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
- The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
- Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
- Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
- Natalizumab De-escalation With Interferon Beta-1b
- Natalizumab Treatment of Progressive Multiple Sclerosis
- Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
- JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
- JC-Virus (JCV) Antibody Program
- Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
- Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
- A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
- A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
- A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
- Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
- A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
- Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
- Tysabri Observational Program
- A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
- Natalizumab (Tysabri) Re-Initiation of Dosing
- Open-Label Natalizumab Safety Extension Study
- Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
- Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
- Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
- Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Clinical trials list
click for details